Abstracts Archive - Page 44 of 2607 - ACR Meeting Abstracts

Abstract Number: 0494 • ACR Convergence 2025
LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Matt McClure¹, Catherine Carriere¹, Kierstin Bell¹, Rex Williams², Geoff Kuesters², Emily Sansevere², Dave Nichols², Arthur Tzianabos² and Jay Rothstein¹, ¹Lifordi Immunotherapeutics, Lebanon, NH, ²Lifordi Immunotherapeutics, Burlington, MA
Background/Purpose: Glucocorticoids (GCs) are the most versatile and efficacious anti-inflammatory drugs rheumatologists have available for patients. Unfortunately, prolonged systemic GC exposure leads to unacceptable toxicities,…
Abstract Number: 0535 • ACR Convergence 2025
Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Chamaida Plasencia-Rodríguez⁴, Alejandro Balsa⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, MADRID, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Inflammatory back pain (IBP) is very relevant for identifying patients at risk of axial spondyloarthritis (axSpA). Mounting evidence has indicated substantial variability in sensitivity…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…
Abstract Number: 0498 • ACR Convergence 2025
Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
Naveen Reddy¹, Narendra Maharaj¹, Pramod Kumar Reddy¹, Mansi Dhananjaya Jakhade¹, Maria Velinova² and Vendel Kemény³, ¹Biologics, Dr. Reddy’s Laboratories Ltd., Hyderabad, India, Hyderabad, India, ²ICON – Early Development Services Van Swietenlaan ⁶ ⁹⁷²⁸ NZ, Groningen, Netherlands, Groningen, Netherlands, ³ICON Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely Rottenbiller utca ¹³ ¹⁰⁷⁷, Budapest, Hungary, Budapest, Hungary
Background/Purpose: Dr. Reddy’s-abatacept (DRL_AB) is being developed as a biosimilar to the reference product (RP) (RP-US licensed Orencia®) and the reference medicinal product (RMP) (RMP-EU…
Abstract Number: 0457 • ACR Convergence 2025
Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
Pratyusha Banik¹, Melody Andrews¹, Sudhakar Pipavath¹ and Namrata Singh², ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of lung cancer with shared risk factors being heavy smoking history and possibly interstitial…
Abstract Number: 0488 • ACR Convergence 2025
Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
Jérôme Avouac¹, Neil Betteridge², Karen Bevers³, Gerd Burmester⁴, Roberto Caporali⁵, Ouafia Bouzid⁶, Thomas Debray⁶, Carole Van der Donckt⁶, James Galloway⁷, Susana Romero-Yuste⁸ and Patrick Verschueren⁹, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²Neil Betteridge Associates, London, United Kingdom, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁶Alfasigma S.p.A., Bologna, Italy, ⁷King's College London, London, United Kingdom, ⁸University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁹Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 0521 • ACR Convergence 2025
Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga³, Yujin Nishioka⁴, Masaki Nojima¹, Takumi Saito⁵, Yu Yamaji⁶, Tomoko Miyashita⁶, Makio Kusaoi⁷, Ken Yamaji⁵ and Naoto Tamura⁸, ¹Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ³Juntendo University, Tokyo, Japan, ⁴Juntendo University, Department of Internal Medicine and Rheumatology, Shizuoka, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, ⁷Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo, Tokyo, Japan, ⁸Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren's disease (pSD) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Patricia Remalante-Rayco¹, Laura Passalent², Manal Alnasser³, Tina Chim¹, Robert Inman¹, Nigil Haroon⁴ and Denis Poddubnyy⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³King Abdulaziz Medical City, Riyadh, Saudi Arabia, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…
Abstract Number: 0776 • ACR Convergence 2025
Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial
Wolfgang Schmidt¹, Arathi Setty², Christian Dejaco³, Andrea Rubbert-Roth⁴, Maria Cid⁵, Tomonori Ishii⁶, Avani D. Joshi², Nathaniel Zerad², Aditi Kadakia⁷, Shaofei Zhao², Weihan Zhao², Ivan Lagunes², Charles Phillips⁸, Daniel Blockmans⁹ and Peter Merkel¹⁰, ¹Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ²AbbVie Inc, North Chicago, IL, ³Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁴Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁶Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ⁷AbbVie Inc, Woburn, MA, ⁸AbbVie Inc, Princeton, NJ, ⁹Department of General Internal Medicine, University Hospitals Leuven; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹⁰University of Pennsylvania, Philadelphia, PA

Background/Purpose: In the SELECT-GCA phase 3 trial, treatment of patients with GCA with upadacitinib 15 mg (UPA15) demonstrated superior rates of disease remission, fewer disease…
Abstract Number: 0772 • ACR Convergence 2025
Redefining When to Biopsy the Kidney in Patients with SLE
Michelle Petri¹, Andrea Fava², Mohamed Atta³, Avi Rosenberg³, Sanchit Sanyal³, Peter Izmirly⁴, Erin Carter⁵, Mala Masson⁶, Michael Belmont⁷, Jennifer Barnas⁸, Jennifer Anolik⁹, Brad Rovin¹⁰ and Jill Buyon⁴, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁷NYU Langone Health, New York, NY, ⁸University of Rochester, Rochester, NY, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰The Ohio State University, Columbus, OH
Background/Purpose: Current ACR, EULAR and KDIGO guidelines recommend kidney biopsy in SLE patients with urine protein to creatinine (UPCR) ratio of >= 0.50 g/g. However,…
Abstract Number: 0766 • ACR Convergence 2025
Effects of Walking During the 6-Minute Walk Test on Cognition in Adults with Knee Replacement
Christine Pellegrini¹, Jongwon Lee¹, Chih-Hsiang Yang¹, Scott Jamieson², Clare Kennerley¹ and Sara Wilcox¹, ¹University of South Carolina, Columbia, SC, ²The University of South Carolina, Columbia, SC
Background/Purpose: The majority of adults with knee replacement remain physically inactive after surgery and are at high risk for Alzheimer’s and related dementias (ADRD). This…
Abstract Number: 0454 • ACR Convergence 2025
Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
Laura Galindo Domínguez¹, Belen Acasuso¹, Vanesa Balboa², Juan Cañete³, Benjamin Fernández-Gutiérrez⁴, Isidoro Gonzalez-Alvaro⁵, jose Luis Pablos⁶, Carmen Bejerano-Herreria⁷, Maite silva⁸, Ignacio rego Pérez⁹, Cristina Ruiz-Romero¹⁰, Francisco J De-Toro-Santos¹¹, Natividad Oreiro¹² and francisco J Blanco¹³, ¹Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Galicia, Spain, ²Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, ³Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴Department of Rheumatology and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain., Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁶Department of Rheumatology, Instituto de Investigación Hospital ¹² de Octubre, Complutense University of Madrid, Madrid, Madrid, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁸Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁹Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, ¹⁰Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, ¹²CHUAC, La Coruna, Spain, ¹³INIBIC-University of A Coruña, A Coruña, Galicia, Spain
Background/Purpose: Optimization of biologic DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six…
Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].